Anti-ADAR1

Item number Size Datasheet Manual SDS Delivery time Quantity Price
A303-883A-T 20 µl (2 blots) -

3 - 9 business days*

131.00€
A303-883A-M 100 µl (10 blots) -

3 - 9 business days*

313.00€
A303-883A 100 µl (100 µg) -

3 - 9 business days*

465.00€
 
Protein function: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded... more
Product information "Anti-ADAR1"
Protein function: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer- associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing- independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication. [The UniProt Consortium]
Keywords: Anti-p136, Anti-ADAR, Anti-IFI-4, Anti-DRADA, Anti-ADAR1, Anti-K88DSRBP, EC=3.5.4.37, Anti-Interferon-inducible protein 4, Anti-136 kDa double-stranded RNA-binding protein, Anti-Double-stranded RNA-specific adenosine deaminase
Supplier: Bethyl Laboratories
Supplier-Nr: A303-883A

Properties

Application: WB, IP, IHC
Antibody Type: Polyclonal
Conjugate: No
Host: Rabbit
Reactivity: Human (Expected: Orangutan, Gorilla, Chimpanzee, White-tufted-ear Marmoset)
Immunogen: synthetic peptide. The epitope recognized by A303-883A-T maps to a region between residue 200 and 250 of human Adenosine Deaminase, RNA-specific using the numbering given in entry NP_001102.2 (GeneID 103).
Format: Antigen Affinity Purified

Handling & Safety

Storage: +4°C
Shipping: +4°C (International: +4°C)
Caution
Our products are for laboratory research use only: Not for administration to humans!
Information about the product reference will follow. more
You will get a certificate here
or to request a certificate of analysis.
Read, write and discuss reviews... more
Customer review for "Anti-ADAR1"
Write a review
or to review a product.
Viewed